ClinicalTrials.gg
RecruitingNCT05482568Updated Apr 20, 2026

A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer

A Phase 1/2 interventional study of SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316 in Advanced Non-small Cell Lung Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-20.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2022; still recruiting 4 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
324
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing trastuzumab rezetecan in Carcinoma, Non-Small-Cell Lung — 10 open to participants now, 11 under way, 2 of them phase 3. trastuzumab rezetecan · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
2nd of 11
324 · median 60
Started
2022
the only one that year
Phase 1/2
2 of 11
1 open now
Primary completion
2026-12
later than 2 of 10 live
Registered
2nd of 11
by date
Lead sponsor
3 of 11
Jiangsu HengRui Medicine Co., Ltd.

Among the 11 studies testing trastuzumab rezetecan in Carcinoma, Non-Small-Cell Lung, this one is the 2nd largest by planned enrollment, is the only one that started in 2022, is one of 2 in phase 1/2, reaches primary completion later than 2 of the 10 other live ones, and was the 2nd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

10 of the 11 studies testing trastuzumab rezetecan in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

About trastuzumab rezetecan

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing trastuzumab rezetecan in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This study was an open, multicenter, dose-increasing/investigational Phase IB/II clinical trial to evaluate the efficacy of SHR-A1811 in combination with other antitumor therapies in subjects with advanced non-small cell lung cancer with HER2 . It can be divided into two parts, Part A is the dose escalation and efficacy exploration study of SHR-A1811 combined with Pyrotinib, and Part B is the dose escalation and efficacy exploration study of SHR-A1811 combined with SHR-1316.

03

Conditions studied

  • Advanced Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to give , signed and dated IRB/EC approved informed consent, willing and able to comply with treatment planning visits, tests and other procedural requirements
  2. When signing the informed consent, the age is 18-75 years old (including both ends), and there is no gender limitation
  3. The score is 0 or 1
  4. The expected survival is ≥12 weeks
  5. Subjects with advanced or non-small cell lung cancer
  6. Formalin fixed, paraffin-embedded tumor tissue blocks or sections of unstained tumor specimens are provided
  7. Subjects who have failed prior standard care or are intolerant to standard care
  8. There is at least one
  9. Vital organs are functioning well
  10. Heart function is good
  11. Agree to

Exclusion criteria

Exclusion Criteria:

  1. There are untreated or active central nervous system (CNS) tumor
  2. Pleural, ascites, or pericardial effusion requiring intervention occurred within 7 days prior to initial administration
  3. Systemic antitumor therapy was performed 4 weeks prior to study initiation
  4. Prior treatment with antibody-conjugated drugs
  5. Received >30 Gy chest radiation within 6 months prior to initial administration
  6. Palliative radiotherapy was completed within 7 days prior to initial administration
  7. Failure to recover from toxicity and/or complications of previous interventions to nCI- ≤1
  8. The half-life of suppressor, moderate inhibitor or strong inducer or moderate inducer is less than 3 or less than 14 days from the date of first drug use, and the shorter is selected
  9. Received systemic therapy within 14 days prior to the first study
  10. Subjects with known or suspected interstitial pneumonia
  11. In the first study, failure to swallow, chronic diarrhea, gastroenteritis, intestinal obstruction, gastrointestinal perforation, postgastrectomy, or colitis, or other medical conditions or special conditions affecting drug administration and absorption occurred within 28 days prior to administration
  12. Presence of any active, known or suspected disease
  13. Have poorly controlled or severe cardiovascular disease
  14. Previous or concurrent
  15. Subjects who developed a severe infection within 28 days prior to the first dose
  16. Active
  17. There were active tuberculosis patients within 1 year before enrollment
  18. There is a history of immunodeficiency
  19. was administered within 28 days prior to initial study administration or is expected to be administered during study treatment
  20. Subjects who are participating in another clinical study or who have had their first dose less than 4 weeks since the end of the previous clinical study (last dose) or 5 half-lives of the study drug, whichever is shorter
  21. Major surgery other than diagnosis or was performed within 28 days prior to initial administration
  22. People who are known to be allergic to sir-A1811, pyrrolitinib, or any of the components of SIR-1316
  23. History of severe allergic reactions to other monoclonal antibody/fusion protein drugs
  24. Female subjects who are pregnant, breast-feeding, or planning to become pregnant during the study
  25. Uncontrolled mental illness and other conditions known to affect the completion of the study process, such as alcohol, drug or substance abuse and detention
  26. Any other conditions that, in the investigator's judgment, may increase the risk of study participation, interfere with study results, or make study participation unsuitable
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
324 participants (estimated)

Study arms

  • Experimental
    SHR-A1811 combined with Pyrotinib/SHR-A1811 combined with SHR-1316

    Drug: SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316

Interventions

  • DrugSHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316

    Drug pages: Trastuzumab rezetecan · Pyrotinib · Adebrelimab

    Drug: SHR-A1811 \& Pyrotinib SHR-A1811: intravenous Pyrotinib:oral Drug: SHR-A1811 \& SHR-1316 SHR-A1811: intravenous SHR-1316: intravenous

06

What researchers measure

Primary outcomes

  1. DLT(Phase I (dose exploration phase) main study endpoint)

    Time frame: 21 days after the first administration of each subject

  2. AE(Phase I (dose exploration phase) main study endpoint)

    Time frame: Two years after the last subject was enrolled in the group

  3. Incidence and severity of serious adverse events (SAE)(Phase I (dose exploration phase) main study endpoint)

    Time frame: Two years after the last subject was enrolled in the group

  4. Objective response rate(The main end points of the second stage (efficacy expansion stage))

    Time frame: Two years after the last subject was enrolled in the group

Secondary outcomes

  1. Toxin binding antibody to shr-a1811(Phase I secondary endpoint)

    Time frame: Two years after the last subject was enrolled in the group

  2. Total antibody to shr-a1811(Phase I secondary endpoint)

    Time frame: Two years after the last subject was enrolled in the group

  3. Plasma concentration of free toxin shr169265(Phase I secondary endpoint)

    Time frame: Two years after the last subject was enrolled in the group

  4. Plasma concentration of pyrroltinib(Phase I secondary endpoint)

    Time frame: Two years after the last subject was enrolled in the group

  5. Plasma concentration of SHR-1316(Phase I secondary endpoint)

    Time frame: Two years after the last subject was enrolled in the group

  6. Anti shr-a1811 antibody positive(Phase I secondary endpoint)

    Time frame: Two years after the last subject was enrolled in the group

  7. The positive status of neutralizing antibody against shr-a1811(Phase I secondary endpoint)

    Time frame: Two years after the last subject was enrolled in the group

  8. Anti shr-1316 antibody positive(Phase I secondary endpoint)

    Time frame: Two years after the last subject was enrolled in the group

  9. The positive status of neutralizing antibody against shr-1316(Phase I secondary endpoint)

    Time frame: Two years after the last subject was enrolled in the group

  10. Objective Response Rate(Phase I secondary endpoint)

    Time frame: Two years after the last subject was enrolled in the group

  11. Duration of response(Phase I secondary endpoint)

    Time frame: Two years after the last subject was enrolled in the group

  12. Progression Free Survival(Phase I secondary endpoint)

    Time frame: Two years after the last subject was enrolled in the group

  13. AE(Phase II secondary study endpoint)

    Time frame: Two years after the last subject was enrolled in the group

  14. Incidence and severity of serious adverse events (SAE)(Phase II secondary study endpoint)

    Time frame: Two years after the last subject was enrolled in the group

  15. Toxin binding antibody to shr-a1811(Phase II secondary study endpoint)

    Time frame: Two years after the last subject was enrolled in the group

  16. Total antibody to shr-a1811(Phase II secondary study endpoint)

    Time frame: Two years after the last subject was enrolled in the group

  17. Plasma concentration of free toxin shr169265(Phase II secondary study endpoint)

    Time frame: Two years after the last subject was enrolled in the group

  18. Plasma concentration of pyrroltinib(Phase II secondary study endpoint)

    Time frame: Two years after the last subject was enrolled in the group

  19. Plasma concentration of SHR-1316(Phase II secondary study endpoint)

    Time frame: Two years after the last subject was enrolled in the group

  20. Anti shr-a1811 antibody positive(Phase II secondary study endpoint)

    Time frame: Two years after the last subject was enrolled in the group

  21. The positive status of neutralizing antibody against shr-a1811(Phase II secondary study endpoint)

    Time frame: Two years after the last subject was enrolled in the group

  22. Anti shr-1316 antibody positive(Phase II secondary study endpoint)

    Time frame: Two years after the last subject was enrolled in the group

  23. The positive status of neutralizing antibody against shr-1316(Phase II secondary study endpoint)

    Time frame: Two years after the last subject was enrolled in the group

  24. Duration of response(Phase II secondary study endpoint)

    Time frame: Two years after the last subject was enrolled in the group

  25. Progression Free Survival(Phase II secondary study endpoint)

    Time frame: Two years after the last subject was enrolled in the group

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Dec 2026, 51 months after the start.

Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's planned 51 months is below that.

Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2022
First posted
Aug 1, 2022
StartActual
Sep 15, 2022
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Apr 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05482568
Responsible party
Sponsor
First posted
Aug 1, 2022
Start date
Sep 15, 2022
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Apr 20, 2026

Study contacts

Suqiang Yu
Contact
suqiang.yu@hengrui.com
+0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Trastuzumab rezetecan · Pyrotinib · Adebrelimab

Start the discussion